Glaukos

GKOS

Market cap $6.07B

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel Virtual Ophthalmology Forum on Tuesday, May 26, 2026, at 1:30 p.m. ET William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026, at.

Novocure and Glaukos led the Medical-Products industry group Thursday after the duo demolished Wall Street's first-quarter expectations.

GKOS beats Q1 estimates with 41% revenue growth, narrows loss and raises 2026 outlook as glaucoma and corneal segments drive momentum.

Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript

While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Glaukos (GKOS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.22 per share a year ago.

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced financial results for the first quarter ended March 31, 2026. Key highlights include: Record net sales of $150.6 million in Q1 2026 increased 41% year-over-year on a reported basis and 39% year-over-year on a constant currency basis. Glaucoma record ne.

GKOS secures a permanent CMS J-code for Epioxa, a move set to streamline reimbursement and expand patient access in keratoconus treatment.

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that it has published its 2025 Sustainability Report. The report highlights the company's continued commitment and progress on its key corporate sustainability priorities. The Sustainability Report can be found on the company's website here. “I am prou.

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Epioxa™ HD / Epioxa™ (“Epioxa”) for the treatment of keratoconus, a rare, sight-threatening disease.